Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK To Fund ‘Artificial Pancreas’ Technology, But Only For Companies That Cut Prices

Executive Summary

The UK’s health technology assessment organization is in favor of funding hybrid closed loop systems for certain people with type 1 diabetes, but only if companies agree to provide such products at more “cost-effective” prices.

You may also be interested in...

Minute Insight: Abbott’s Libre 3 Finds Route To NHS Patients With YpsoMed And CamDiab Partnership

Abbott’s flagship CGM, the FreeStyle Libre 3, will soon become available in the UK through the National Health Service as part of a hybrid closed-loop system utilizing Ypsomed and CamDiab’s technologies.

Medtech Monthly, Ep. 4: The Future Of Diabetes Tech

In this edition of the Medtech Monthly podcast, Medtech Insight editor Reed Miller talks to UK-based reporter Barnaby Pickering to get a overview of the highly competitive diabetes tech and future of this dynamic, consumer-centric market.

Medtech Monthly, Ep. 2: Where Does Diabetes Tech Stand In 2022?

In this edition of Medtech Monthly, Robert Gabbay, chief scientific and medical officer for the American Diabetes Association talked to Medtech Insight about diabetes tech, where it's headed, and what it could mean for preventative care.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts